Alto Neuroscience Inc. earnings per share and revenue
On Nov 12, 2025, ANRO reported earnings of -0.52 USD per share (EPS) for Q3 25, beating the estimate of -0.68 USD, resulting in a 23.65% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.97% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.54 USD, with revenue projected to reach -- USD, implying an increase of 3.85% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Alto Neuroscience Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Alto Neuroscience Inc. reported EPS of -$0.52, beating estimates by 23.65%, and revenue of $0.00, 0% as expectations.
How did the market react to Alto Neuroscience Inc.'s Q3 2025 earnings?
The stock price moved up 5.97%, changed from $13.40 before the earnings release to $14.20 the day after.
When is Alto Neuroscience Inc. expected to report next?
The next earning report is scheduled for Mar 20, 2026.
What are the forecasts for Alto Neuroscience Inc.'s next earnings report?
Based on 12
analysts, Alto Neuroscience Inc. is expected to report EPS of -$0.54 and revenue of -- for Q4 2025.